Previous 10 | Next 10 |
SAN DIEGO , May 7, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, ...
NetworkNewsWire Editorial Coverage : Gene therapies are gaining growing attention within the medical sector. Gene therapies help restore or replace the body’s damaged or missing genes. Groundbreaking treatments can stop the spread of cancer cells, cause cancer cells to die. G...
TrovaGene ( TROV ) announced that it had achieved positive preclinical findings using its drug onvansertib in combination with AbbVie's ( ABBV ) Venclexta (Venetoclax). This is in the early stage of testing, but it could provide a very good alternative for these patients, in that they won't ...
Gainers: Atossa Genetics (NASDAQ: ATOS ) +28% . Immunic (NASDAQ: IMUX ) +22% . Akari Therapeutics (NASDAQ: AKTX ) +19% . Superconductor Technologies (NASDAQ: SCON ) +18% . X4 Pharmaceuticals (NASDAQ: XFOR ) +17% . Hasbro (NASDAQ: HAS ) +16% . Twitter (NYSE: TWTR ) +16% . Trova...
TrovaGene (NASDAQ: TROV ) +22% on positive onvansertib data . More news on: TrovaGene, Inc., Akari Therapeutics, Plc, Hasbro, Inc., Stocks on the move, Read more ...
Trovagene (NASDAQ: TROV ) reports preclinical data on the combination of onvansertib and AbbVie's (NYSE: ABBV ) Venclexta (venetoclax) in an AML cell model is known to be resistant to venetoclax. More news on: TrovaGene, Inc., AbbVie Inc., Healthcare stocks news, Stocks on the move,...
SAN DIEGO , April 23, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers,...
BP Prudhoe Bay Royalty Trust (NYSE: BPT ) -11% . More news on: BP Prudhoe Bay Royalty Trust, Social Reality, Inc., Marathon Patent Group, Inc., Stocks on the move, Read more ...
ChinaNet Online Holdings (NASDAQ: CNET ) +39% . More news on: ChinaNet Online Holdings, Inc., TrovaGene, Inc., JMU Limited, Stocks on the move, Read more ...
Trovagene (NASDAQ: TROV ) inks an agreement with Lincoln Park Capital Fund, LLC for the purchase 382,166 common shares and five -year pre-funded warrants at $3.925 per share and warrant. Concurrently, Lincoln Park has also agreed to buy five-year warrants to purchase up to 382,166 common s...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO , May 7, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, today a...
SAN DIEGO , May 6, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing its drug, onvansertib, to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga&...
SAN DIEGO , April 28, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, ...